XOMA Ltd. and Aragen Bioscience, Inc. have entered into an agreement under which Aragen Bioscience will provide its clients with access to XOMA’s Human Engineering technology for antibody humanization. Financial terms were not disclosed.
“Access to XOMA’s extensive technology and expertise in antibody humanization allows Aragen Bioscience to provide its customers a seamless transition from murine antibody discovery and sequencing to antibody testing, variable domain humanization, stable and transient expression, cell line development and pre-clinical production services. The addition of XOMA’s technology to our services enables our clients to quickly access antibody humanization technology that is recognized throughout the industry as cutting-edge,” said Aragen Bioscience’s president and chief executive officer, Rick Srigley.
“We believe that pairing our Human Engineering technology and know-how with Aragen Bioscience’s cell line development experience and expertise is an excellent way to make this technology available to the pharmaceutical and biotech industries,” said Patrick J. Scannon, M.D., Ph.D., executive vice president and chief scientific officer at XOMA.